IP Library Granted Patent US 8,513,304
Granted Patent B2
US 8,513,304 · App. 13/680,623 · Granted Aug 20, 2013

Topical formulation

Inventors: Edward T. Kisak (San Diego, CA); John M. Newsam (La Jolla, CA); Dominic King-Smith (San Diego, CA); Pankaj Karande (Troy, NY); Samir Mitragotri (Goleta, CA)
Assignee: Nuvo Research Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,513,304
App. No.
13/680,623
Granted
Aug 20, 2013
Kind
B2
Abstract

It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.

Claims (20)

1. A topical formulation comprising: (i) an active agent selected from at least one of lidocaine or tetracaine, (ii) a first compound, (iii) a second compound, and (iv) a thickener, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.

2. The topical formulation of claim 1 , wherein the first compound and second compound are selected from the group consisting of isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate.

3. The topical formulation of claim 2 , wherein the active agent is a combination of lidocaine and tetracaine.

4. The topical formulation of claim 2 , wherein the first compound comprises isopropyl myristate and the second compound comprises oleic acid.

5. The topical formulation of claim 2 , wherein the first compound comprises isopropyl myristate and the second compound comprises glyceryl oleate.

6. The topical formulation of claim 2 , wherein the first compound comprises sodium lauryl sulfoacetate and the second compound comprises isopropyl myristate.

7. The topical formulation of claim 2 , wherein the first compound comprises oleic acid and the second compound comprises glyceryl oleate.

8. The topical formulation of claim 2 , wherein the first compound comprises oleic acid and the second compound comprises sodium lauryl sulfoacetate.

9. The topical formulation of claim 2 , wherein the first compound comprises glyceryl oleate and the second compound comprises sodium lauryl sulfoacetate.

10. The topical formulation of claim 2 , further comprising one or more biologically acceptable excipients.

11. The topical formulation of claim 10 , wherein the thickener is polyvinyl alcohol.

12. The topical formulation of claim 2 , wherein the total concentration of the first compound and the second compound is up to about 50 wt %, 40 wt %, 35 wt %, 30 wt %, 25 wt %, 20 wt %, 15 wt %, 10 wt %, 7.5 wt % or 5 wt %, per unit volume of the formulation.

13. The topical formulation of claim 2 , wherein the total concentration of the first compound and the second compound is in the range of from about 1 wt % to about 20 wt %, per unit volume of the formulation.

14. The topical formulation of claim 2 , wherein the total concentration of the first compound and the second compound is in the range of from about 1 wt % to about 15 wt %, per unit volume of the formulation.

15. The topical formulation of claim 2 , wherein the total concentration of the first compound and the second compound is in the range of from about 1 wt % to about 10 wt %, per unit volume of the formulation.

16. The topical formulation of claim 2 , wherein the total concentration of the first compound and the second compound is in the range of from about 1 wt % to about 5 wt %, per unit volume of the formulation.

17. The topical formulation of claim 2 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:9 to about 9:1.

18. The topical formulation of claim 2 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:3 to about 3:1.

19. The topical formulation of claim 2 , wherein the weight ratio of the first compound to the second compound is in the range of from about 1:2 to about 2:1.

20. The topical formulation of claim 2 , wherein the weight ratio of the first compound to the second compound is about 1:1.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 4, 2017
From: NUVO RESEARCH INC.
To: CRESCITA THERAPEUTICS INC.
Reel/Frame 040840/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2016
From: NUVO RESEARCH INC.
To: CRESCITA THERAPEUTICS INC.
Reel/Frame 040485/0021 →
CHANGE OF NAME Recorded Jun 20, 2013
From: FQUBED, INC.
To: NUVO RESEARCH US INC.
Reel/Frame 030661/0899 →
MERGER Recorded Jun 12, 2013
From: NUVO RESEARCH US INC.
To: NUVO RESEARCH US, INC.
Reel/Frame 030596/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2013
From: NUVO RESEARCH US, INC.
To: NUVO RESEARCH INC.
Reel/Frame 030596/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2013
From: KISAK, EDWARD T.; NEWSAM, JOHN M.; KING-SMITH, DOMINIC; KARANDE, PANKAJ; MITRAGOTRI, SAMIR
To: FQUBED, INC.
Reel/Frame 030577/0924 →
Continuity (4)
Continuation 12848792 · Aug 2, 2010
Continuation In Part 12281561
Provisional Application 60778847 · Mar 6, 2006
Related Publication 20130079404A1 · Mar 28, 2013